Proposals to introduce harmonised classification and labelling of certain substances and to update or delete the harmonised classification and labelling of certain other substances have been submitted to the European Chemicals Agency (‘Agency’) pursuant to Article 37 of Regulation (EC) No 1272/2008. The Committee for Risk Assessment of the Agency (RAC) adopted opinions [The opinions are accessible via the following website:https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/] on those proposals, after having taken account of the comments received from the parties concerned. Those RAC opinions are:
Opinion of 15 March 2019 concerning 1,2,4-triazole,
Opinion of 15 March 2019 concerning 1,4-dioxane,
Opinion of 15 March 2019 concerning benzyl salicylate,
Opinion of 15 March 2019 concerning flumioxazin (ISO),
Opinion of 15 March 2019 concerning mancozeb (ISO),
Opinion of 15 March 2019 concerning M-factors for long-term aquatic hazard for the copper substances listed in Commission Regulation (EU) 2016/1179,
Opinion of 15 March 2019 concerning N-{2-[[1,1'-bi(cyclopropyl)]-2-yl]phenyl}-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide; sedaxane,
Opinion of 15 March 2019 concerning N-methoxy-N-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide; pydiflumetofen,
Opinion of 15 March 2019 concerning p-cymene; 1-isopropyl-4-methylbenzene,
Opinion of 15 March 2019 concerning p-mentha-1,3-diene; alpha-terpinene; 1-isopropyl-4-methylcyclohexa-1,3-diene,
Opinion of 15 March 2019 concerning prothioconazole,
Opinion of 15 March 2019 concerning (R)-p-mentha-1,8-diene; d-limonene,
Opinion of 15 March 2019 concerning thiophanate-methyl,
Opinion of 15 March 2019 concerning tolclofos-methyl (ISO); O-(2,6-dichloro-p-tolyl) O,O-dimethyl thiophosphate,
Opinion of 15 March 2019 concerning tolpyralate,
Opinion of 15 March 2019 concerning trinickel disulphide,
Opinion of 13 June 2019 concerning azamethiphos,
Opinion of 13 June 2019 concerning 2-phenoxyethanol,
Opinion of 13 June 2019 concerning 2,2-dibromo-2-cyanoacetamide,
Opinion of 13 June 2019 concerning 3-aminomethyl-3,5,5-trimethylcyclohexylamine,
Opinion of 13 June 2019 concerning 6,6'-di-tert-butyl-2,2'-methylenedi-p-cresol,
Opinion of 13 June 2019 concerning diflufenican (ISO) N-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide,
Opinion of 13 June 2019 concerning imidacloprid (ISO); 1-(6-chloropyridin-3-ylmethyl)-N-nitroimidazolidin-2-ylidenamine,
Opinion of 13 June 2019 concerning pyriofenone,
Opinion of 13 June 2019 concerning S-abscisic acid,
Opinion of 13 June 2019 concerning tetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate,
Opinion of 20 September 2019 concerning 1,2-epoxy-4-epoxyethylcyclohexane,
Opinion of 20 September 2019 concerning 4-methylpentan-2-one,
Opinion of 20 September 2019 concerning boric acid; diboron trioxide; tetraboron disodium heptaoxide hydrate; disodium tetraborate anhydrous; orthoboric acid sodium salt; disodium tetraborate decahydrate; disodium tetraborate pentahydrate,
Opinion of 20 September 2019 concerning citric acid,
Opinion of 20 September 2019 concerning clomazone,
Opinion of 20 September 2019 concerning desmedipham,
Opinion of 20 September 2019 concerning dimethomorph,
Opinion of 20 September 2019 concerning emamectin benzoate,
Opinion of 20 September 2019 concerning esfenvalerate (ISO) (S)-α-cyano-3-phenoxybenzyl (S)-2-(4-chlorophenyl)-3-methylbutyrate,
Opinion of 20 September 2019 concerning ethametsulfuron-methyl (ISO),
Opinion of 20 September 2019 concerning mecoprop-P (ISO); (R)-2-(4-chloro-2-methylphenoxy)propionic acid and its salts,
Opinion of 20 September 2019 concerning methyl salicylate,
Opinion of 20 September 2019 concerning phenmedipham (ISO),
Opinion of 20 September 2019 concerning trifloxystrobin (ISO),
Opinion of 20 September 2019 concerning triticonazole,
Opinion of 5 December 2019 concerning 1,4-dimethylnaphthalene,
Opinion of 5 December 2019 concerning (3aS,5S,6R,7aR,7bS,9aS,10R,12aS,12bS)-10-[(2S,3R,4R,5R)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-5,6-dihydroxy-7a,9a-dimethylhexadecahydro-3H-benzo[c]indeno[5,4-e]oxepin-3-one; 24-epibrassinolide,
Opinion of 5 December 2019 concerning 3-methylpyrazole,
Opinion of 5 December 2019 concerning carbendazim (ISO); methyl benzimidazol-2-ylcarbamate,
Opinion of 5 December 2019 concerning cypermethrin cis/trans +/- 40/60; (RS)-α-cyano-3-phenoxybenzyl (1RS,3RS;1RS,3SR)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate,
Opinion of 5 December 2019 concerning imazamox (ISO); (RS)-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid,
Opinion of 5 December 2019 concerning tetrafluoroethylene,
Opinion of 5 December 2019 concerning thiamethoxam (ISO); 3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine,
Opinion of 5 December 2019 concerning trinexapac-ethyl (ISO); ethyl 4-[cyclopropyl(hydroxy)methylene]-3,5-dioxocyclohexanecarboxylate.